Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · IEX Real-Time Price · USD
46.84
-1.65 (-3.40%)
At close: Jul 17, 2024, 4:00 PM
46.70
-0.14 (-0.30%)
After-hours: Jul 17, 2024, 4:28 PM EDT

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc.
Kymera Therapeutics logo
Country United States
Founded 2015
IPO Date Aug 21, 2020
Industry Biotechnology
Sector Healthcare
Employees 187
CEO Dr. Nello Mainolfi M.D., Ph.D.

Contact Details

Address:
500 North Beacon Street, 4th Floor
Watertown, Massachusetts 02472
United States
Phone 857-285-5314
Website kymeratx.com

Stock Details

Ticker Symbol KYMR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001815442
CUSIP Number 501575104
ISIN Number US5015751044
Employer ID 81-2992166
SIC Code 2836

Key Executives

Name Position
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Director
Dr. Bruce L. Booth DPHIL, Ph.D. Co-Founder and Chairman
Bruce N. Jacobs CFA Chief Financial Officer
Dr. Jared A. Gollob M.D. Chief Medical Officer
Dr. Jeremy G. Chadwick Ph.D. Chief Operating Officer
Ellen V. Chiniara Esq., J.D. Chief Legal Officer and Corporate Secretary
Karen Weisbach Head of People and Culture
Dr. Juliet Williams B.A Ph.D. Head of Research

Latest SEC Filings

Date Type Title
Jul 16, 2024 144 Filing
Jul 15, 2024 144 Filing
Jul 9, 2024 144 Filing
Jul 9, 2024 144 Filing
Jul 8, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
Jun 13, 2024 144 Filing
Jun 13, 2024 144 Filing
Jun 12, 2024 144 Filing
Jun 12, 2024 144 Filing